• Je něco špatně v tomto záznamu ?

Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells

T. Knox, E. Sahakian, D. Banik, M. Hadley, E. Palmer, S. Noonepalle, J. Kim, J. Powers, M. Gracia-Hernandez, V. Oliveira, F. Cheng, J. Chen, C. Barinka, J. Pinilla-Ibarz, NH. Lee, A. Kozikowski, A. Villagra,

. 2019 ; 9 (1) : 6136. [pub] 20190416

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028919

Grantová podpora
R01 CA204806 NCI NIH HHS - United States
R21 CA184612 NCI NIH HHS - United States

Histone deacetylases (HDACs) are involved in diverse cellular regulatory mechanisms including non-canonical functions outside the chromatin environment. Several publications have demonstrated that selective HDAC inhibitors (HDACi) can influence tumor immunogenicity and the functional activity of specific immune cells. In particular, the selective inhibition of HDAC6 has been reported to decrease tumor growth in several malignancies. However, there is still no clarity about the cellular components mediating this effect. In this study, we evaluated the HDAC6i Nexturastat A as a priming agent to facilitate the transition of the tumor microenvironment from "cold" to "hot", and potentially augment immune check-point blockade therapies. This combination modality demonstrated to significantly reduce tumor growth in syngeneic melanoma tumor models. Additionally, we observed a complete neutralization of the up-regulation of PD-L1 and other immunosuppressive pathways induced by the treatment with anti-PD-1 blockade. This combination also showed profound changes in the tumor microenvironment such as enhanced infiltration of immune cells, increased central and effector T cell memory, and a significant reduction of pro-tumorigenic M2 macrophages. The evaluation of individual components of the tumor microenvironment suggested that the in vivo anti-tumor activity of HDAC6i is mediated by its effect on tumor cells and tumor-associated macrophages, and not directly over T cells. Overall, our results indicate that selective HDAC6i could be used as immunological priming agents to sensitize immunologically "cold" tumors and subsequently improve ongoing immune check-point blockade therapies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028919
003      
CZ-PrNML
005      
20210114155329.0
007      
ta
008      
210105s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-019-42237-3 $2 doi
035    __
$a (PubMed)30992475
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Knox, Tessa $u The George Washington University, Washington, DC, USA.
245    10
$a Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells / $c T. Knox, E. Sahakian, D. Banik, M. Hadley, E. Palmer, S. Noonepalle, J. Kim, J. Powers, M. Gracia-Hernandez, V. Oliveira, F. Cheng, J. Chen, C. Barinka, J. Pinilla-Ibarz, NH. Lee, A. Kozikowski, A. Villagra,
520    9_
$a Histone deacetylases (HDACs) are involved in diverse cellular regulatory mechanisms including non-canonical functions outside the chromatin environment. Several publications have demonstrated that selective HDAC inhibitors (HDACi) can influence tumor immunogenicity and the functional activity of specific immune cells. In particular, the selective inhibition of HDAC6 has been reported to decrease tumor growth in several malignancies. However, there is still no clarity about the cellular components mediating this effect. In this study, we evaluated the HDAC6i Nexturastat A as a priming agent to facilitate the transition of the tumor microenvironment from "cold" to "hot", and potentially augment immune check-point blockade therapies. This combination modality demonstrated to significantly reduce tumor growth in syngeneic melanoma tumor models. Additionally, we observed a complete neutralization of the up-regulation of PD-L1 and other immunosuppressive pathways induced by the treatment with anti-PD-1 blockade. This combination also showed profound changes in the tumor microenvironment such as enhanced infiltration of immune cells, increased central and effector T cell memory, and a significant reduction of pro-tumorigenic M2 macrophages. The evaluation of individual components of the tumor microenvironment suggested that the in vivo anti-tumor activity of HDAC6i is mediated by its effect on tumor cells and tumor-associated macrophages, and not directly over T cells. Overall, our results indicate that selective HDAC6i could be used as immunological priming agents to sensitize immunologically "cold" tumors and subsequently improve ongoing immune check-point blockade therapies.
650    _2
$a zvířata $7 D000818
650    _2
$a antiflogistika $x terapeutické užití $7 D000893
650    _2
$a protinádorové látky imunologicky aktivní $x terapeutické užití $7 D000074322
650    _2
$a antigeny CD274 $x imunologie $7 D060890
650    _2
$a histondeacetylasa 6 $x antagonisté a inhibitory $x imunologie $7 D000073864
650    _2
$a inhibitory histondeacetylas $x terapeutické užití $7 D056572
650    _2
$a imunologická tolerance $x účinky léků $7 D007108
650    _2
$a makrofágy $x účinky léků $x imunologie $7 D008264
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a nádory $x farmakoterapie $x imunologie $7 D009369
650    _2
$a antigeny CD279 $x antagonisté a inhibitory $x imunologie $7 D061026
650    _2
$a nádorové mikroprostředí $x účinky léků $7 D059016
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sahakian, Eva $u H. Lee Moffitt, Tampa, FL, USA.
700    1_
$a Banik, Debarati $u The George Washington University, Washington, DC, USA.
700    1_
$a Hadley, Melissa $u The George Washington University, Washington, DC, USA.
700    1_
$a Palmer, Erica $u The George Washington University, Washington, DC, USA.
700    1_
$a Noonepalle, Satish $u The George Washington University, Washington, DC, USA.
700    1_
$a Kim, Jennifer $u The George Washington University, Washington, DC, USA.
700    1_
$a Powers, John $u H. Lee Moffitt, Tampa, FL, USA.
700    1_
$a Gracia-Hernandez, Maria $u The George Washington University, Washington, DC, USA.
700    1_
$a Oliveira, Vasco $u Hospital Episcopal San Lucas, Ponce, PR, USA.
700    1_
$a Cheng, Fengdong $u The George Washington University, Washington, DC, USA.
700    1_
$a Chen, Jie $u The George Washington University, Washington, DC, USA.
700    1_
$a Barinka, Cyril $u Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Vestec, Czech Republic.
700    1_
$a Pinilla-Ibarz, Javier $u H. Lee Moffitt, Tampa, FL, USA.
700    1_
$a Lee, Norman H $u The George Washington University, Washington, DC, USA.
700    1_
$a Kozikowski, Alan $u StarWise LLC, Madison, WI, USA.
700    1_
$a Villagra, Alejandro $u The George Washington University, Washington, DC, USA. avillagra@gwu.edu.
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 9, č. 1 (2019), s. 6136
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30992475 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114155327 $b ABA008
999    __
$a ok $b bmc $g 1609254 $s 1120099
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 9 $c 1 $d 6136 $e 20190416 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
GRA    __
$a R01 CA204806 $p NCI NIH HHS $2 United States
GRA    __
$a R21 CA184612 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace